Posted on 05/01/2010 in Pharmacy Supplier News Actavis has announced the launch of Valaciclovir in a number of countries in the European Economic Area, including the UK, after its patent expired in recent days.
The pharmacy products supplier explained that the therapy is used to treat herpes virus infections and that its patents expired on December 20th and 21st 2009.
Other than the UK, countries that the product, which is manufactured by the firm in a facility in Iceland, has been launched in include Italy, Norway and France.
It is also set to be rolled out in a number of other European markets in the future, explained Actavis, which recently announced that its hospitals division has signed a deal with Bioluz to develop and manufacture injectable drugs in ready-to-administer containers.
"Valaciclovir Actavis is the generic equivalent of GlaxoSmithKline's Valtrex/Zelitrex. The generic drug from Actavis is available in 500 mg tablets and 1,000 mg in some markets," the company concluded.Other news stories from 05/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
